Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
451.8 USD | +0.94% | +2.79% | +11.31% |
May. 22 | Vertex Pharmaceuticals Insider Sold Shares Worth $6,795,294, According to a Recent SEC Filing | MT |
May. 21 | ADDvise Group’s Axelerist Bags $1.4 Million Order for Medical, Lab Equipment | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 29.4 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.26% | 115B | B+ | ||
+11.84% | 106B | B+ | ||
-6.88% | 24.69B | B+ | ||
-1.16% | 21.97B | B | ||
-5.10% | 19.27B | A- | ||
-12.19% | 17.56B | B | ||
-39.36% | 17.32B | A- | ||
+5.26% | 14.03B | C+ | ||
+32.78% | 12.13B | C+ | ||
-31.83% | 7.77B | D |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- VRTX Stock
- Ratings Vertex Pharmaceuticals Incorporated